Omeros Stock Forecast, Price & News

+0.22 (+1.40 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume790,316 shs
Average Volume589,739 shs
Market Capitalization$998.69 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.

Omeros logo

About Omeros

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.


Zacks: Analysts Expect Omeros Co. (NASDAQ:OMER) to Announce -$0.48 EPS
Zacks: Analysts Expect Omeros Co. (NASDAQ:OMER) to Announce -$0.48 EPS
September 14, 2021 |
Omeros: The Prize Is Nigh (Again) - Seeking Alpha
Omeros: The Prize Is Nigh (Again) - Seeking Alpha
September 14, 2021 |
Omeros: The Prize Is Nigh (Again)
Omeros: The Prize Is Nigh (Again)
September 14, 2021 |
Analyzing FibroGen (NASDAQ:FGEN) & Omeros (NASDAQ:OMER)
Analyzing FibroGen (NASDAQ:FGEN) & Omeros (NASDAQ:OMER)
September 9, 2021 |
Omeros (NASDAQ:OMER) Receives Buy Rating from HC Wainwright
Omeros (NASDAQ:OMER) Receives Buy Rating from HC Wainwright
September 7, 2021 |
-$0.48 EPS Expected for Omeros Co. (NASDAQ:OMER) This Quarter
-$0.48 EPS Expected for Omeros Co. (NASDAQ:OMER) This Quarter
August 27, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.00 out of 5 stars

Medical Sector

376th out of 1,351 stocks

Pharmaceutical Preparations Industry

185th out of 664 stocks

Analyst Opinion: 3.6Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Omeros (NASDAQ:OMER) Frequently Asked Questions

Is Omeros a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Omeros stock.
View analyst ratings for Omeros
or view top-rated stocks.

What stocks does MarketBeat like better than Omeros?

Wall Street analysts have given Omeros a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Omeros wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Omeros' next earnings date?

Omeros is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Omeros

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) announced its quarterly earnings data on Sunday, August, 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.50) by $0.04. The biopharmaceutical company had revenue of $28.82 million for the quarter, compared to analyst estimates of $25.95 million.
View Omeros' earnings history

How has Omeros' stock been impacted by COVID-19 (Coronavirus)?

Omeros' stock was trading at $15.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OMER stock has increased by 6.3% and is now trading at $15.98.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OMER?

5 analysts have issued 1 year price objectives for Omeros' shares. Their forecasts range from $21.00 to $100.00. On average, they expect Omeros' share price to reach $40.60 in the next twelve months. This suggests a possible upside of 154.1% from the stock's current price.
View analysts' price targets for Omeros
or view top-rated stocks among Wall Street analysts.

Who are Omeros' key executives?

Omeros' management team includes the following people:
  • Gregory A. Demopulos, Chairman, President & Chief Executive Officer
  • Michael A. Jacobsen, Chief Financial Officer, Treasurer & VP (LinkedIn Profile)
  • George A. Gaitanaris, Chief Scientific Officer & Vice President-Science
  • J. Steven Whitaker, Chief Medical Officer & Vice President
  • Peter B. Cancelmo, Secretary, Vice President & General Counsel

What is Gregory A. Demopulos' approval rating as Omeros' CEO?

17 employees have rated Omeros CEO Gregory A. Demopulos on Gregory A. Demopulos has an approval rating of 74% among Omeros' employees.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Who are Omeros' major shareholders?

Omeros' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.33%), State Street Corp (2.17%), Geode Capital Management LLC (1.66%), Stifel Financial Corp (1.60%), Northern Trust Corp (1.11%) and Cpwm LLC (1.10%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Michael A Jacobsen and Thomas J Cable.
View institutional ownership trends for Omeros

Which major investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BlackRock Inc., Federated Hermes Inc., Nuveen Asset Management LLC, Bank of America Corp DE, Susquehanna International Group LLP, SG3 Management LLC, and Bank of New York Mellon Corp. Company insiders that have sold Omeros company stock in the last year include Gregory A Md Demopulos, Michael A Jacobsen, and Thomas J Cable.
View insider buying and selling activity for Omeros
or view top insider-selling stocks.

Which major investors are buying Omeros stock?

OMER stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Royal Bank of Canada, Millennium Management LLC, Simplex Trading LLC, GSA Capital Partners LLP, Woodward Diversified Capital LLC, Citadel Advisors LLC, and Group One Trading L.P..
View insider buying and selling activity for Omeros
or or view top insider-buying stocks.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $15.98.

How much money does Omeros make?

Omeros has a market capitalization of $998.69 million and generates $73.81 million in revenue each year. The biopharmaceutical company earns $-138,060,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Omeros have?

Omeros employs 277 workers across the globe.

Does Omeros have any subsidiaries?

The following companies are subsidiares of Omeros: Nura.

When was Omeros founded?

Omeros was founded in 1994.

What is Omeros' official website?

The official website for Omeros is

Where are Omeros' headquarters?

Omeros is headquartered at 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at (206) 676-5000.

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.